Curaxis Pharmaceutical Corp. (CURX) is “One to Watch”

Curaxis Pharmaceutical Corp। is an emerging specialty pharmaceutical company. They have a pipeline of product candidates in Alzheimer’s disease and oncology. The Company bases their therapeutic platform on the hypothesis that many diseases of aging may be caused by age-related changes in the function of the hypothalamic-pituitary-gonadal (HPG) axis. Founded in 2001, Curaxis Pharmaceutical Corp. has their headquarters in Swampscott, Massachusetts.
The HPG axis is a hormonal endocrine feedback loop. It controls development, reproduction and aging in animals. The building of this drug development platform is on the premise that hormones associated with this feedback loop are beneficial early in life, when they promote growth and development. However, they are harmful later in life when the mechanism for feedback is compromised. Consequently, this leads to disease processes, such as pathologies associated with Alzheimer’s disease and various cancers.Curaxis Pharmaceutical Corp। believes their discovery of similar hormonal signaling mechanisms at the cellular level in brain tissue from Alzheimer’s patients and in multiple tumors will enable them to develop major new treatments for Alzheimer’s disease and numerous cancers।The Company’s most advanced product candidate is Memryte (generic name VP4896). This proprietary, small, biodegradable implant consists of leuprolide acetate and a polymer. Memryte is a patented treatment, which has shown the potential for treating and halting the progression of Alzheimer’s Disease (AD).Curaxis Pharmaceutical’s clinical programs include ALADDIN I/103, which completed Phase II clinical trial for the treatment of women aged 65 years or older with mild to moderate Alzheimer’s disease. They also include ALADDIN II/104, which completed Phase II clinical trial for the treatment of men aged 65 years or older with mild to moderate Alzheimer’s disease. Additionally, they include ALADDIN 105 that completed Phase I clinical trial for healthy women aged 45 to 70 years and men aged 50 to 70 years.In May, Curaxis Pharmaceutical Corp. announced that the Company’s lead drug hormone product for Alzheimer’s disease, Memryte, was named by the editors of R&D Directions magazine as one of the top “100 Great Investigational Drugs in Development” today. In their tenth annual list of promising clinical compounds, R&D Directions cited this Curaxis drug, which addresses the pathologies of Alzheimer’s disease via multiple pathways. These include beta amyloid, tau phosphorylation, inflammation and aberrant cell cycling, as a unique clinical approach in targeting the brain disorder.

Curaxis Pharmaceutical Corporation Announces Key Changes to Its Board of Directors and Management Team in Progression Toward Clinical Trials

Curaxis Pharmaceutical Corporation (OTCQB: CURX) ("Curaxis" or the "Company") today announced that it has replaced the Company's Board of Directors (the "Board") and the executive management team to better position the Company for its next phase of growth and development. Joining the Board will beTimothy Wright, Terence Novak, Michael George, Michael Miller, Ivan Gothner and Stephen Leary. Dr. Bert Spilker, who is a current Board member, will continue to serve on the Board. All other present members of the Board have elected to resign from their Board and officer positions. Mr. Wright will assume the duties of Chairman of the Board and interim Chief Executive Officer, and Judith Geaslen will continue to serve as the Company's Vice President of Finance.The new Board brings to Curaxis a wealth of experience and comprehensive knowledge of life sciences, operations and strategic management in the area of pharmaceuticals. In addition, the newly appointed Board members have significant experience in all of the necessary industry arenas to execute the Company's business plan on an accelerated basis.Curaxis is positioned to be a leader in the treatment of Alzheimer's disease with its drug candidate Memryte, and the new team will enhance the success of this position and bolster the drug's movement to eventual commercialization. After providing evidence of efficacy in clinical trial results, this talented and professional team of experts will now move to the final critical steps to commercialization of Memryte, Curaxis' lead hormone drug candidate for the treatment of Alzheimer's and multiple cancers.Outgoing Chairman of the Board Patrick S. Smith stated, "We are honored that these highly experienced and esteemed industry veterans have agreed to join our Board and executive management team, and look forward to the contribution they will make to the Company's future."The newly appointed members of the Board bring over 175 combined years of life science and pharmaceutical industry experience and have held top senior management positions at notable companies such as DuPont Merck, Covidien (Mallinckrodt), Elan Pharmaceuticals and Urocor, Inc., among others.Newly appointed Chairman of the Board Timothy Wright stated, "We thank the departing Board and management for their efforts on behalf of the Company and its shareholders, and are very excited to develop Curaxis' Alzheimer's disease drug candidate and other pipeline candidates. We are also pleased that Dr. Spilker will continue on the Board, as his extensive experience in clinical trials is a tremendous asset as the Company moves toward commercialization of Memryte."